Form 4: Allogene Therapeutics CFO Sells Shares to Cover Tax Obligations

Geoffrey M. Parker, CFO of Allogene Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On October 21, 2024, Geoffrey M. Parker, the Chief Financial Officer of Allogene Therapeutics, Inc. (ALLO), sold 36,404 shares of common stock at a weighted average price of $2.84.
• The sale was to cover tax withholding obligations related to the vesting of restricted stock units and was not a discretionary trade.
• Following the transaction, Parker beneficially owns 1,131,988 shares of Allogene Therapeutics common stock, which includes 3,974 shares acquired through an employee stock purchase program on September 15, 2024.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transaction is a routine sale to cover tax obligations, not necessarily indicative of a negative outlook, but could be perceived negatively by some investors.

Positives

• The transaction is a 'sell to cover' for tax obligations, which is a common practice and doesn't necessarily indicate a negative outlook on the company.
• Parker still holds a significant number of shares (1,131,988) after the sale, indicating continued investment in the company's future.

Negatives

• The sale of shares, even for tax purposes, could be perceived negatively by some investors.

Risks

• Market perception of insider selling, regardless of the reason, can sometimes negatively impact stock price.

Industry Context

Sales of shares to cover tax obligations are common among executives, especially after vesting of stock options or restricted stock units. It's a routine part of executive compensation and financial planning.

Comparison to Industry Standards

• Executive compensation practices, including equity grants and subsequent 'sell to cover' transactions, are standard across publicly traded companies, particularly in the biotech industry.
• Comparing Parker's holdings and transactions to those of executives at similar-stage biotech companies (e.g., CRISPR Therapeutics, Beam Therapeutics) would provide a benchmark for assessing the magnitude and frequency of such transactions.

Stakeholder Impact

• The sale could have a minor impact on shareholders if it contributes to downward pressure on the stock price, although the effect is likely to be minimal given the reason for the sale.

Key Dates